AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21339632
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of human rhGH administered from day 1 to day 7
Trial: 21339632
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride (placebo) administered from day 1 to day 7
Trial: 27222760
Drug: Paliperidone extended-release
RxNorm normalized name: Paliperidone Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone extended-release
Trial: 11791086
Drug: HRT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT group (estradiol 2 mg and norethisterone acetate 1 mg)
Trial: 10604491
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg HCTZ once daily
Trial: 26858122
Drug: Durvalumab 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg
Trial: 26858122
Drug: Durvalumab 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 20 mg/kg every 4 weeks plus tremelimumab 3 mg/kg
Trial: 26858122
Drug: Durvalumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 3 mg/kg, 10 mg/kg, 15 mg/kg, or 20 mg/kg every 4 weeks, or 10 mg/kg every 2 weeks, plus tremelimumab 1 mg/kg, 3 mg/kg, or 10 mg/kg every 4 weeks for six doses then every 12 weeks for three doses
Trial: 18372684
Drug: Inertial mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inertial mechanical loading (2.5 G at the feet decreasing to 1 G at the heart) for 60 min daily during 21 days of head-down bed rest
Trial: 2508190
Drug: Misonidazole (MISO)
RxNorm normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misonidazole (MISO) 500 mg administered four hours prior to irradiation
Trial: 73353
Drug: morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine (0.1 mg/kg)
Trial: 20337772
Drug: Isotretinoin 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 0.3 mg/kg
Trial: 15820533
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg of metyrapone
Trial: 15820533
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of cocaine
Trial: 10482089
Drug: timolol 0.5%,
RxNorm normalized name: Timolol 0.5%, Bimatoprost 0.01% Ophthalmic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timolol 0.5%, twice daily
Trial: 8739868
Drug: Antiseptic-mucolytic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiseptic-mucolytic saline
Trial: 1754859
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily for 6 weeks (double-blind alternating treatment)
Trial: 1754859
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 6 weeks (double-blind alternating treatment)
Trial: 1754859
Drug: Ranitidine continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine continued for 4 weeks (single-blind treatment)
Trial: 1754859
Drug: Placebo until
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo until relapse or maximum 8 weeks (single-blind treatment)
Trial: 2883987
Drug: pindolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol (5 mg)
Trial: 7102530
Drug: metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol (100 mg)
Trial: 7102530
Drug: inhaled fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled fenoterol (0.4 mg)
Trial: 31448738
Drug: Polypill group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill group (hydrochlorothiazide 12·5 mg, aspirin 81 mg, atorvastatin 20 mg, and enalapril 5 mg or valsartan 40 mg)
Trial: 16143732
Drug: Telephone-administered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered cognitive-behavioral therapy (T-CBT)
Trial: 10710122
Drug: UR-7247 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UR-7247 2.5 mg
Trial: 10710122
Drug: UR-7247 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UR-7247 5 mg
Trial: 10710122
Drug: UR-7247 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UR-7247 10 mg
Trial: 9015796
Drug: 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg phenylalanine
Trial: 8195856
Drug: Brodimoprim, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodimoprim, 200 mg once-a-day on the first day and 100 mg once-a-day on the following days
Trial: 8195856
Drug: Cefaclor, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor, 40 mg/Kg/day in three doses
Trial: 28089902
Drug: Olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg plus azelnidipine 16 mg
Trial: 28089902
Drug: Olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg plus trichlormethiazide 1 mg
Trial: 18339052
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate combined with vitamins C (500 mg) and B(6) (75 mg) and proline
Trial: 12662184
Drug: RPR100893 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPR100893 (1 mg)
Trial: 12662184
Drug: RPR100893 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPR100893 (5 mg)
Trial: 12662184
Drug: RPR100893 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPR100893 (20 mg)
Trial: 9385040
Drug: Acetaminophen (APAP)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP) administration (group A)
Trial: 9385040
Drug: KAKKONTO at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAKKONTO at 100 mg/kg (group K) in rats
Trial: 9385040
Drug: KAKKONTO at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAKKONTO at two different doses
Trial: 1333097
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K treatment during the last 6 weeks prior to delivery
Trial: 28641925
Drug: 3g oral
RxNorm normalized name: Fosfomycin Tromethamine 3g Oral granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g oral ManNAc
Trial: 28641925
Drug: 6g oral
RxNorm normalized name: Sodium Sulfate 17.5g, Potassium Sulfate 3.13g, Magnesium Sulfate 1.6g Oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6g oral ManNAc
Trial: 28641925
Drug: 10g oral
RxNorm normalized name: CytoCarn 10g Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10g oral ManNAc
Trial: 25537481
Drug: Pasireotide (300-1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide (300-1,200 μg bid)
Trial: 23887841
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (0.6 mg/kg rt-PA plus eptifibatide 135 mcg/kg bolus and a 2-hour infusion at 0.75 mcg/kg per minute)
Trial: 23887841
Drug: Standard rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard rt-PA (0.9 mg/kg)
Trial: 12837218
Drug: lamivudine treatment
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine treatment
Trial: 8744700
Drug: Domperidone administration
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone administration
Trial: 2666707
Drug: Dilzem (180‐300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilzem (180‐300 mg/daily)
Trial: 2666707
Drug: Corinfar (30‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corinfar (30‐60 mg/daily)
Trial: 998645
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% preparation
Trial: 998645
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% preparation
Trial: 998645
Drug: Lidocaine 0.25%
RxNorm normalized name: Bupivacaine Hydrochloride/Epinephrine/Lidocaine 0.25%-1 MG/1 ML-1% Injection Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 0.25% preparation
Trial: 998645
Drug: Lidocaine 0.50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 0.50% preparation
Trial: 998645
Drug: Lidocaine 0.75%
RxNorm normalized name: Bupivacaine Hydrochloride/Epinephrine/Lidocaine 0.75%-1 MG/1 ML-1% Injection Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 0.75% preparation
Trial: 998645
Drug: Lidocaine 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.0% preparation
Trial: 30731375
Drug: Antibiotics use
RxNorm normalized name: Antibiotics for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics use
Trial: 28599898
Drug: Chlorhexidine-alcohol 26-mL
RxNorm normalized name: chlorhexidine / isopropyl alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine-alcohol 26-mL single-step applicator
Trial: 28599898
Drug: Povidone-iodine aqueous
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine aqueous scrub and paint 236-mL wet skin tray
Trial: 22511916
Drug: Intermittent oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent oral FTC/TDF (Monday, Friday and within 2 hours after sex)
Trial: 22511916
Drug: Post-coital doses
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-coital doses of FTC/TDF
Trial: 8053584
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil infusion at 0.2 microgram.kg‐1.h‐1
Trial: 8053584
Drug: Intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sufentanil infusion at 0.2 microgram.kg‐1.h‐1
Trial: 2927302
Drug: Glucose polymers
RxNorm normalized name: glucose polymers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose polymers (3 g.kg‐1 in a 50% solution)
Trial: 31743467
Drug: Placebo 'dummy'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 'dummy' treatment
Trial: 23859389
Drug: Inhaling ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaling ketamine 1 mg/kg (Group Ki)
Trial: 23859389
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of ketamine 1 mg/kg (Group Kv)
Trial: 23859389
Drug: Inhaling normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaling normal saline 10 ml (Group C)
Trial: 2044734
Drug: Bricanyl Turbuhaler
RxNorm normalized name: terbutaline sulfate Oral Solution [Bricanyl]
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bricanyl Turbuhaler (dry powder terbutaline 0.5 mg q.i.d)
Trial: 2044734
Drug: Bricanyl metered
RxNorm normalized name: terbutaline sulfate Oral Solution [Bricanyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bricanyl metered dose inhaler (MDI) (terbutaline 0.5 mg q.i.d)
Trial: 25958709
Drug: Antibiotics discontinued
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics discontinued promptly after CRP level < 10 mg/L in group Ia
Trial: 25958709
Drug: Antibiotics continued
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics continued until all bacterial cultures were negative in group Ib
Trial: 25958709
Drug: Antibiotics continued
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics continued until CRP < 10 mg/L in group IIa
Trial: 25958709
Drug: Antibiotics continued
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics continued until all bacterial cultures were negative in group IIb
Trial: 19857666
Drug: Mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mycophenolic acid (MPA) C(0) levels below 1.0 to 1.5 microg/mL at day 7
Trial: 19857666
Drug: MPAG C(0)
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MPAG C(0) levels above 100 to 150 microg/mL at day 7
Trial: 15113721
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (25 mg Zn)
Trial: 7913986
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) administered antenatally, intrapartum, and postnatally
Trial: 25432081
Drug: Pazopanib 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 5 mg/ml instilled 3 times daily (n = 72)
Trial: 25432081
Drug: Pazopanib 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 5 mg/ml instilled 4 times daily (n = 74)
Trial: 25432081
Drug: Pazopanib 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 10 mg/ml instilled 2 times daily (n = 73)
Trial: 25432081
Drug: Pazopanib 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 10 mg/ml instilled 3 times daily (n = 73)
Trial: 25432081
Drug: Pazopanib 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 10 mg/ml instilled 4 times daily (n = 72)
Trial: 25432081
Drug: Ranibizumab injection
RxNorm normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab injection administered once every 4 weeks (n = 73)
Trial: 25432081
Drug: Placebo eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops instilled 4 times daily (n = 73)
Trial: 21498494
Drug: Spinal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal morphine 100 µg + TAP block with bupivacaine 2 mg kg(‐1) (S(M)T(LA))
Trial: 21498494
Drug: Spinal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal morphine 100 µg + TAP block with saline (S(M)T(S))
Trial: 16421418
Drug: Dose-Intensive Epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-Intensive Epirubicin and Cyclophosphamide (DI-EC)
Trial: 19468030
Drug: Standard-Dose Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-Dose Chemotherapy (SD-CT)
Trial: 16760197
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg Methylphenidate (MPH)
Trial: 16760197
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg Atomoxetine (ATX)
Trial: 24675657
Drug: N(G)-monomethyl-L-arginine
RxNorm normalized name: N(G)-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)-monomethyl-L-arginine
Trial: 31425478
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab treatment (0.5 mg in 0.05 ml via six intravitreal injections over 6 months)
Trial: 21237502
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg, two tablets once daily)
Trial: 18083770
Drug: Conventional tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tidal volume (V(T)) of 12 ml/kg without positive end-expiratory pressure (PEEP)
Trial: 18083770
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume (V(T)) of 6 ml/kg and 10 cmH(2)O PEEP
Trial: 15454803
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (hemoglobin concentration, 70 g/L)
Trial: 15454803
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (hemoglobin concentration, 100 g/L)
Trial: 11688554
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (Nonspi 5R = Np)
Trial: 11688554
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (ViskenR = Vs)
Trial: 11688554
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations of pindolol
Trial: 22106853
Drug: OROS MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OROS MPH 72 mg/day
Trial: 22106853
Drug: OROS MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OROS MPH 54 mg/day
Trial: 21501093
Drug: EpiCor(®) (EP)
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EpiCor(®) (EP) 500 mg
Trial: 17874825
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg polaprezinc (zinc group)
Trial: 11520252
Drug: Bivalent Hib-HB
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivalent Hib-HB vaccine with DTP, OPV or IPV, DTaP, M-M-R(II)
Trial: 3289583
Drug: Topical gentamicin
RxNorm normalized name: gentamicin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gentamicin solution
Trial: 31394015
Drug: No traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No traditional medicines (n = 19)
Trial: 26105600
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg once daily until progression/unacceptable toxicity)
Trial: 26105600
Drug: Gemcitabine/cisplatin (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine/cisplatin (GP) [G 1250 mg/m(2) i.v. days 1 and 8 (3-weekly cycle); P 75 mg/m(2) i.v. day 1, (3-weekly cycle) for up to four cycles]
Trial: 1452917
Drug: Streptokinase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase treatment (anterior infarction)
Trial: 1452917
Drug: Streptokinase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase treatment (inferior infarction)
Trial: 2982266
Drug: Naloxone (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (1.4 mg/hr for 3 hours)
Trial: 27236772
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg twice per day (b.i.d.) with dose titration
Trial: 24140184
Drug: Placebo titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo titration
Trial: 27236772
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg b.i.d. (nonrandomized patients)
Trial: 22466511
Drug: Endobronchial valves
RxNorm normalized name: AmproMed for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial valves treatment
Trial: 7802571
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (1 g of cephalothin sodium intravenously 30 minutes before the procedure and 500 mg of cephalexin orally every 6 hours for 3 days after the procedure)
Trial: 353833
Drug: L-tryptophan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (2 g) + oxprenolol (80 mg)
Trial: 31172867
Drug: Tablet computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet computer monitoring of upper limb exercise program
Trial: 31331372
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal therapy (HFNT) set at 37°C and 60 L/min
Trial: 31331372
Drug: Noninvasive ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive ventilation (NIV) applied through a mask with pressure support mode, PEEP set at 3-5 cmH2O, tidal volume between 6-8 ml/kg
Trial: 22080588
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg b.i.d. for 12 weeks
Trial: 21943027
Drug: Voclosporin (low-dose)
RxNorm normalized name: ethinyl estradiol
DrugBank: Voclosporin (DB11693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voclosporin (low-dose)
Trial: 21943027
Drug: Voclosporin (medium-dose)
DrugBank: Voclosporin (DB11693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voclosporin (medium-dose)
Trial: 21943027
Drug: Voclosporin (high-dose)
DrugBank: Voclosporin (DB11693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voclosporin (high-dose)
Trial: 12620524
Drug: High-fat, low-carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat, low-carbohydrate oral supplement (16.7% protein, 55.1% fat, 28.2% CHO)
Trial: 9926766
Drug: Modified Widman
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Widman flap and topical application of saturated citric acid at pH 1 for 3 minutes
Trial: 11271288
Drug: High-sodium lactobionate/raffinose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sodium lactobionate/raffinose solution
Trial: 11271288
Drug: High-potassium lactobionate/raffinose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-potassium lactobionate/raffinose solution